Business Context and Reporting Period
Company: uniQure N.V.
Filing Type: Form 8-K (Current Report)
Date: September 24, 2025
Context: The filing announces positive topline data from the pivotal Phase I/II study of AMT-130, a gene therapy candidate for the treatment of Huntington's disease. The report details clinical trial outcomes, regulatory interactions with the U.S. Food and Drug Administration (FDA), and future development plans.
Key Financial Metrics
This Form 8-K is a current report focused on clinical trial updates and regulatory events. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. Investors should refer to the Company's most recent Form 10-Q or 10-K for financial data.
Material Changes and Clinical Results
The filing reports significant clinical progress for AMT-130 based on 36-month follow-up data for 29 treated patients (17 high dose, 12 low dose) compared to propensity score-matched external controls from the Enroll-HD dataset.
- Primary Endpoint (High Dose): Achieved a statistically significant 75% slowing of disease progression as measured by the composite Unified Huntington's Disease Rating Scale (cUHDRS) (p=0.003).
- Key Secondary Endpoint (High Dose): Achieved a statistically significant 60% slowing of disease progression as measured by Total Functional Capacity (TFC) (p=0.033).
- Other Secondary Endpoints (High Dose):
- Symbol Digit Modalities Test (SDMT): 88% slowing of progression (p=0.057).
- Stroop Word Reading Test (SWRT): 113% slowing of progression (nominal p=0.002).
- Total Motor Score (TMS): 59% slowing of progression (nominal p=0.174).
- Biomarker: Mean reduction in cerebrospinal neurofilament light protein (CSF NfL) of -8.2% from baseline.
- Safety: AMT-130 was generally well-tolerated. No new drug-related serious adverse events have been observed since December 2022. Most common adverse events were procedure-related and resolved.
Guidance, Outlook, and Risks
Regulatory Pathway: The Company plans to discuss the data with the FDA at a pre-Biologic License Application (BLA) meeting later in 2025. The intention is to submit a BLA in the first quarter of 2026.
Future Trials: A fourth U.S.-based cohort is currently enrolling to evaluate high-dose AMT-130 in up to 6 patients with lower striatal volumes.
Risks and Uncertainties:
- Topline data may not be predictive of later data readouts.
- Regulatory approval is not guaranteed; the FDA may require additional Phase III or confirmatory studies.
- Risks related to funding operations and raising additional capital.
- Potential variability in the robustness of disease progression measurements.
Investor Verification Checklist
- Verify the statistical methodology used for the propensity score-matched external control comparison against the Enroll-HD dataset.
- Confirm the specific timeline and agenda for the upcoming pre-BLA meeting with the FDA.
- Review the Company's cash runway and capital requirements to fund the BLA submission and potential Phase III trials.
- Monitor the enrollment and safety data of the fourth cohort (patients with lower striatal volumes).
- Assess the durability of the 36-month efficacy data in the context of long-term follow-up requirements.